{"id":"W4234185004","doi":"10.1200/jco.2013.31.18_suppl.cra9003","title":"Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; GNAQ; Selumetinib; Clinical endpoint; Hazard ratio; Internal medicine; Temozolomide; Progression-free survival; Gastroenterology; Randomization; Dacarbazine; Phases of clinical research; Oncology; Randomized controlled trial; Cancer; Chemotherapy; Confidence interval; KRAS","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001596637,0.001872232,0.001887321,0.0004762786,0.0003487488,0.001055599,0.001025965,0.001420589,0.004672723],"category_scores_gemma":[0.001254062,0.0007812402,0.001009268,0.0003817828,0.001014703,0.001133351,0.0003423381,0.002898528,0.001055873],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001061955,"about_ca_system_score_gemma":0.001382805,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001042301,"about_ca_topic_score_gemma":0.002925672,"domain_scores_codex":[0.9996526,0.0001897959,0.00001328323,0.00005293916,0.00002462172,0.00006674519],"domain_scores_gemma":[0.9991674,0.0001635636,0.0001622116,0.00005749084,0.00004730989,0.0004020206],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8620694,0.06021541,0.002722265,0.000542052,0.0007924108,0.0001614639,0.0002305251,0.002562285,0.03113303,0.0003486912,0.002669655,0.03655267],"study_design_scores_gemma":[0.6006982,0.3877251,0.004657466,0.00002821194,0.0003187831,0.00016157,0.00008384566,0.001515206,0.002859997,0.0002968166,0.001626803,0.00002793697],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919171,0.001340449,0.0004950875,0.0004967746,0.0001915333,0.003045052,0.00087847,0.0001015206,0.001534013],"genre_scores_gemma":[0.9898969,0.001210453,0.001285509,0.0007496912,0.000162012,0.002966379,0.001027506,0.00003053186,0.002671035],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004672723,"threshold_uncertainty_score":0.01563185,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1176640819480776,"score_gpt":0.4830187535876331,"score_spread":0.3653546716395555,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}